Rockefeller Capital Management
OVID icon

Rockefeller Capital Management’s Ovid Therapeutics OVID Stock Holding History

Rockefeller Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.88K Hold
4,000
– – ﹤0.01% 4041
2025
Q4 		$6.52K Buy
+4,000
New +$6.16K ﹤0.01% 3982

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Rockefeller Capital Management's OVID Position: Q1 2026 in Review

Rockefeller Capital Management held its Ovid Therapeutics (OVID) position steady in Q1 2026 at 4,000 shares worth $8.88K. The position accounts for ﹤0.01% of the portfolio, ranked #4041.

Rockefeller Capital Management first reported a position in OVID in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Rockefeller Capital Management held 4,000 shares of Ovid Therapeutics worth $8.88K as of Q1 2026.
  • Rockefeller Capital Management left its Ovid Therapeutics share count unchanged in Q1 2026.
  • Ovid Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4041 holding.
  • Rockefeller Capital Management first reported a position in Ovid Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.